SOSV

SOSV, established in 1995 and headquartered in Princeton, New Jersey, is a global venture capital firm specializing in early-stage investments. It focuses on deep tech innovations in the health and environmental sectors, supporting founders with breakthrough technologies through its HAX and IndieBio startup development programs. SOSV provides resources, facilities, and lab equipment to accelerate product development and scale, with a track record of helping its portfolio companies secure subsequent funding rounds led by top-tier investors.

Hugh Bowen

Associate

Weichang Ge

Analyst

Bradford Higgins

Venture Partner

Katie Hoffman

General Partner

Mohan Iyer

General Partner

Benjamin Joffe

Partner

Ji Ke

Partner

Stephen McCann

CFO and General Partner

Carthach McCarthy

CFO

Paul Monaghan

Principal

Brian Murphy

Finance Director

Eric Ramsay

Analyst

Sabriya Stukes Ph.D

Partner

Past deals in Biotechnology

Hoofprint Biome

Series A in 2025
Hoofprint Biome is a biotechnology company that develops probiotics and natural enzymes to enhance the sustainability of ruminant livestock production. Their products improve cattle health and digestive care by reducing methane emissions, thereby enabling the livestock industry to adopt more sustainable practices through microbiome engineering.

PunaBio

Series A in 2025
PunaBio is a Buenos Aires-based company that develops biological products aimed at enhancing agricultural productivity through environmentally friendly methods. By utilizing extremophile microorganisms, PunaBio focuses on improving crop nutrition, which contributes to increased yields and better crop quality. Their products are designed to enable farmers to cultivate crops on degraded soils and restore and enrich agricultural land sustainably. This approach not only helps improve farmers' productivity but also promotes sustainable agricultural practices.

InnSight Technology

Seed Round in 2025
InnSight Technology is a biotechnology company focused on enhancing diagnostics and evaluation of eye diseases. The company develops innovative ophthalmic devices, including a novel hand-held biosensor designed for the detection of anterior ophthalmic injuries. Additionally, InnSight Technology works on advanced nanotechnology-based medical devices aimed at addressing specific clinical needs in ophthalmology. By providing these tools, the company seeks to improve ocular care for clinicians and their patients.

Fermeate

Seed Round in 2025
Fermeate is a stealth-mode biotechnology company that specializes in photomolecular fermentation technology. This innovative approach aims to enhance sustainability and efficiency within the biomanufacturing industry.

Materia Bioworks

Seed Round in 2025
Materia Bioworks is a pioneering company that develops data-driven informatics tools to facilitate the creation and adoption of sustainable biomaterials. Their AI-powered platform streamlines the process of developing and manufacturing biomaterial products, from sourcing materials to final production. This enables material scientists, product developers, suppliers, and converters to accelerate and enhance their work in biomaterial applications, fostering a more sustainable future across various industries.

Prellis Biologics

Series C in 2025
Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Avalo

Series A in 2025
Avalo is a plant biology company that employs interpretable machine learning, genomic discovery, and evolutionary theory to innovate crop development for future agricultural needs. Utilizing AI-assisted plant breeding, Avalo ensures that all its products are non-GMO and promote natural biodiversity. The company's core technology is a discovery engine that efficiently identifies the genetic foundations of complex traits, significantly shortening the time and reducing the costs associated with developing new crops. By focusing on traits such as drought tolerance, water-use efficiency, and nutrient density, Avalo's platform enhances crop evolution to adapt to changing climate conditions. This approach allows researchers to improve crop quality while providing diagnostic forecasting and gene discovery capabilities, ultimately advancing agricultural practices.

PunaBio

Series A in 2025
PunaBio is a Buenos Aires-based company that develops biological products aimed at enhancing agricultural productivity through environmentally friendly methods. By utilizing extremophile microorganisms, PunaBio focuses on improving crop nutrition, which contributes to increased yields and better crop quality. Their products are designed to enable farmers to cultivate crops on degraded soils and restore and enrich agricultural land sustainably. This approach not only helps improve farmers' productivity but also promotes sustainable agricultural practices.

Hoofprint Biome

Series A in 2025
Hoofprint Biome is a biotechnology company that develops probiotics and natural enzymes to enhance the sustainability of ruminant livestock production. Their products improve cattle health and digestive care by reducing methane emissions, thereby enabling the livestock industry to adopt more sustainable practices through microbiome engineering.

Afynia Laboratories

Seed Round in 2025
Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Oxyle

Seed Round in 2025
Oxyle AG is a Swiss company based in Zurich that specializes in wastewater treatment aimed at removing persistent and toxic micropollutants from water sources. Established in 2020, the company has developed a novel technology that effectively degrades hazardous substances, including pharmaceuticals, personal-care products, endocrine-disrupting chemicals, pesticides, and industrial chemicals. Oxyle serves a diverse clientele, including the pharmaceutical, biotech, chemical, food and beverage sectors, research laboratories, hospitals, and wastewater treatment facilities. Its innovative approach not only helps clients comply with regulatory standards but also offers a sustainable alternative to wastewater incineration, thereby contributing to reduced CO2 emissions.

Particella

Convertible Note in 2025
Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

RyboDyn

Pre Seed Round in 2025
RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to detect and eliminate cancer from within the body. The company is dedicated to advancing scientific breakthroughs that lead to new classes of treatments, providing significant improvements in medicine. RyboDyn's work is particularly concentrated on creating upgraded therapies for serious diseases, including terminal conditions, with the goal of enhancing patient outcomes and expanding treatment options.

Proton Intelligence

Seed Round in 2024
Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Ten63 Therapeutics

Series A in 2024
Ten63 Therapeutics is a biotechnology company focused on developing innovative therapeutics for challenging diseases, particularly those involving targets previously considered undruggable. Founded in 2017 and based in Chapel Hill, North Carolina, the company utilizes its proprietary platform, COPPER, which integrates advanced artificial intelligence and state-of-the-art physical models to explore vast chemical spaces. By employing low-residual, machine learning-based computational chemistry alongside superlinear search algorithms, Ten63 Therapeutics aims to identify and optimize drug candidates effectively. Their approach includes proprietary scaffold redesign and hopping technology, enabling the screening of trillions of molecules to predict resistance and redesign antibodies. This combination of techniques positions Ten63 Therapeutics at the forefront of developing durable treatments for some of the most lethal diseases.

Giraffe Bio

Seed Round in 2024
Giraffe Bio specializes in developing biomolecular technology to enhance the efficiency and sustainability of critical mineral extraction. Their platform tailors biomolecules to the specific geology of each mine, boosting metal recovery, reducing water consumption, and minimizing environmental impact. This is achieved by integrating biology, artificial intelligence, and hardware to optimize extraction processes.

AlkaLi Labs

Convertible Note in 2024
AlkaLi Labs is a biotechnology research company based in San Francisco, California, established in 2023. The company focuses on developing biological solutions to harness domestic mineral resources. Currently operating in stealth mode, AlkaLi Labs aims to innovate in the field of biotechnology, leveraging biological processes to unlock valuable minerals.

BioSapien

Seed Round in 2024
BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Unlocked Labs

Seed Round in 2024
Unlocked Labs specializes in developing innovative probiotics aimed at addressing chronic health conditions by utilizing genetically optimized microbial strains. The company focuses on activating dormant microbial abilities to effectively digest compounds that can lead to health issues. Their first product targets the risk of kidney stones by breaking down stone-forming compounds derived from healthy foods like leafy vegetables. Unlocked Labs employs alternative regulatory pathways to expedite the availability of safe and effective probiotic solutions for consumers. By harnessing the natural detoxifying capabilities of symbiotic microbes, their products aim to reduce acid levels in the body, making them both affordable and accessible to a wide audience.

BioLattice

Seed Round in 2024
BioLattice is a biotechnology company focused on developing tissue-engineered cornea technology. Their primary goal is to provide a viable alternative to donor tissue for full-thickness corneal transplants. The company's innovative technology offers a corneal prototype with vision-correcting capabilities, aiming to restore sight for patients requiring corneal transplants.

ViAn Therapeutics

Seed Round in 2024
VIAN Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop intended to replace traditional injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical trials, VIAN aims to meet significant unmet medical needs in the retinal disease market, which is valued at $15 billion. Additionally, the company is engaged in the creation of peptide drugs that enhance efficacy and safety for treating both ophthalmic and oncology-related conditions by targeting angiogenesis, thereby offering patients improved health outcomes.

Asterix Foods

Convertible Note in 2024
Asterix Foods is a biotechnology company based in Tel Aviv, Israel, founded in 2022. The company specializes in developing protein production using plant-cell culture techniques. Its platform focuses on creating bioactive proteins for food that are scalable, functional, and complex. Asterix Foods aims to provide users with plant cell-cultured and animal-free proteins, contributing to innovative and sustainable food solutions.

Sci-Lume Labs

Seed Round in 2024
Sci-Lume Labs specializes in the development of innovative, bio-based and biodegradable fibers designed to replace conventional petrochemical fibers like nylon and polyester. Their high-performance materials maintain the functionality and versatility of traditional synthetics while addressing environmental concerns, catering to textile and apparel manufacturers seeking sustainable alternatives.

Quorum Earth

Seed Round in 2024
Quorum Earth, based in Brooklyn, New York, is a pioneering agricultural technology company. It specializes in the development of innovative, eco-friendly pesticides, harnessing the power of the fungal kingdom to create products that are safe for the planet and effective in controlling pests. Currently, the company operates in stealth mode.

Exosomm

Seed Round in 2024
Exosomm is an innovative foodtech start-up focused on developing nutritional solutions derived from natural milk exosomes. The company was founded based on research from Hadassah Medical Center, led by Prof. Reif's team. Exosomm's flagship product is a specialized food formula designed for patients suffering from inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. This product utilizes a patented active anti-inflammatory ingredient sourced from milk exosomes, which are isolated using a natural and environmentally friendly process. By targeting health and immunity, Exosomm aims to provide effective solutions for individuals with specific dietary needs.

Capra Biosciences

Convertible Note in 2024
Capra Biosciences is a biotechnology company focused on the efficient and low-carbon production of everyday chemicals through innovative bioreactor technology. The company has developed a biofilm bioreactor platform that aims to enhance the bio-manufacturing process by significantly reducing downstream processing requirements and associated costs. This technology facilitates the production of a variety of bio-based chemicals, including hydrophobic products like retinol and performance lubricants, thus advancing sustainable practices in the chemical industry.

OneSkin

Series A in 2024
OneSkin Inc. is a biotechnology company focused on developing innovative solutions to enhance skin health and combat aging. Founded by a team of PhDs and longevity scientists, the company has created a proprietary peptide, OS-01, which has been validated to reduce the biological age of skin by minimizing the accumulation of aged cells, enhancing cellular repair, and fortifying the epidermal barrier. OneSkin offers a flagship product, the OS-01 Topical Supplement, which is designed to be suitable for all skin types and is made from high-quality vegan ingredients. In addition to its product line, OneSkin specializes in creating advanced 3D human skin models for research and testing purposes, providing in vitro services to assess the efficacy and safety of cosmetic ingredients without the use of animals. Incorporated in 2016 and based in San Francisco, OneSkin is dedicated to advancing the understanding of skin biology and developing effective anti-aging solutions.

Synplexity

Seed Round in 2024
Synplexity, based in New Castle, Delaware, specializes in biotechnology. It offers mutational scanning and multiplexed gene synthesis services, leveraging artificial intelligence. The company's platform, utilizing microdroplets as microreactors, enables the creation of multiplex gene libraries, benefiting various sectors such as therapeutics, biomanufacturing, agriculture, and climate systems.

Laguna Bio

Seed Round in 2024
Laguna Bio is a biotechnology company based in Berkeley, California, founded in 2022. The company focuses on drug discovery, specifically developing a platform that activates and expands the innate immune system to combat cancer. Laguna Bio specializes in enhancing a specific type of T cell that targets solid tumors, aiming to improve the efficacy of bispecific antibody drugs. By increasing the immune response against these tumors, the company seeks to provide innovative solutions that may help patients survive cancer more effectively.

FREZENT

Seed Round in 2024
FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

NanoPlume

Seed Round in 2024
NanoPlume is a biomaterial company specializing in the large-scale production of innovative biomaterials, notably Bio-Aerogel. It manufactures advanced insulating biomaterials and aerogels, designed to enhance energy and space efficiency, and promote circularity across various industries. The company employs organic and recycled feedstocks, along with green technology, to minimize waste and reduce energy consumption. Its products aim to improve cold chain logistics by insulating cargo boxes, reducing payload and energy consumption, and extending battery range.

DisperseBio

Seed Round in 2024
DisperseBio is a Biotechnology Research firm developing a mechanism to counter microbial contamination on natural surfaces like human body.

Huue

Convertible Note in 2024
Huue is a company focused on providing sustainable dyeing solutions for the denim and textile industries, specifically through the use of bio-synthesized indigo dyes. By employing fermentation biotechnology, the company utilizes naturally occurring microorganisms to produce colors, which significantly reduces the reliance on toxic chemicals traditionally used in dye production. This innovative approach not only enhances the environmental sustainability of the denim supply chain but also offers a greener alternative for fashion and textile manufacturers seeking to create eco-friendly products. Huue's commitment to harnessing renewable resources positions it as a leader in the movement towards more sustainable practices in the industry.

Gatehouse Bio

Convertible Note in 2024
Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Sóliome

Seed Round in 2024
Sóliome is a biotechnology company founded in 2021 and based in San Francisco, California. The company specializes in developing protein-based sunscreens designed to be safe for both the skin and the environment. These innovative products aim to reduce inflammation and skin damage caused by traditional sunscreens, which often contain harmful xenobiotic ingredients that can absorb into the skin and contribute to ecological harm. Sóliome's approach allows customers to protect their skin from harmful rays without the adverse effects associated with conventional sunscreen formulations.

Minutia

Seed Round in 2024
Minutia is focused on developing innovative solutions for Type 1 Diabetes through stem cell-derived transplants that incorporate nanosensors. The company specializes in creating subcutaneous insulin-producing cell transplants that are immune-evasive and capable of real-time monitoring via proprietary cell-based sensors. This approach aims to address common challenges associated with transplants and seeks to provide a functional cure for diabetes. By advancing both transplantation techniques and monitoring capabilities, Minutia aspires to transform the clinical landscape of diabetes management and cell replacement therapies.

BioMetallum

Seed Round in 2024
BioMetallum is a biomining company specializing in sustainable metal extraction. It designs and develops solutions, primarily focused on lithium, using microorganisms to enhance efficiency and minimize environmental impact. The company's services promote a circular economy, aiming to enable a healthier, more sustainable society.

Calyx

Funding Round in 2024
Calyx develops advanced sensor platforms that monitor various parameters in poultry and livestock, utilizing cutting-edge technology to address complex challenges in the industry. The company specializes in gas sensor technology that detects airborne chemical emissions through innovative sensors patterned with viruses that bind to specific gas molecules. These sensors provide high specificity and sensitivity, changing color in response to different gases and their concentrations. By integrating artificial intelligence, computer vision technology, and data science, Calyx aims to enhance environmental monitoring and improve health outcomes for livestock and poultry, offering commercial customers effective solutions to track daily environmental changes.

Asta Bio

Seed Round in 2024
Asta Bio is a biotechnology company specializing in the development of radiotherapeutics for cancer treatment. It focuses on combining the alpha-emitting radioisotope 211-Astatine with multivalent single-domain antibodies to deliver targeted alpha radiation to tumor cells, sparing healthy cells. This approach aims to effectively destroy cancer cells by breaking their DNA strands.

DNAzyme

Pre Seed Round in 2024
DNAzyme is a biotechnology company specializing in the development of enzymes derived from Antarctic extremophile microorganisms as active ingredients for skin health applications. Utilizing recombinant DNA repair technology, the company produces highly pure enzymes at an industrial scale, enabling clinicians to create innovative solutions for skin health and rejuvenation in both the cosmetic and pharmaceutical industries.

Tinkeso Therapeutics

Seed Round in 2024
Tinkeso Therapeutics is a biotechnology company specializing in the development of innovative cell therapies for treating cancer and autoimmune diseases. The company focuses on creating off-the-shelf, allogeneic chimeric antigen receptor (CAR) engineered natural killer T (NKT) cell therapies. These therapies use NKT cells to target and destroy cancer cells or modulate the immune response in autoimmune conditions, aiming to increase treatment accessibility and scalability.

Bugbiome

Seed Round in 2024
BugBiome is a biotechnology company that develops eco-friendly bio-repellents to create natural pest control products. It focuses on identifying and enhancing beneficial microbes that deter pests organically, providing an alternative to traditional chemical methods. The company aims to minimize environmental impact and promote sustainable pest management practices, potentially benefiting sectors such as agriculture and households.

heXem bio

Seed Round in 2024
heXem bio specializes in recording solutions for the early development of humans for longevity.

Semion

Convertible Note in 2024
Restoring crops' ability to defend against pests.

ZiO Health

Convertible Note in 2024
ZiO Health is a biotechnology company that focuses on transforming laboratory testing through its proprietary pocket-sized technology, which allows for point-of-care diagnostics. By combining advanced biosensor technology with machine learning algorithms, ZiO Health provides real-time testing results tailored to each patient's unique profile. This innovative approach enables users to measure, test, and detect the molecular composition of various substances, facilitating personalized health insights. The company's devices aim to optimize health management and enhance patient outcomes, allowing individuals to conduct quality home diagnostics and take proactive steps in preventing illness.

Fermeate

Seed Round in 2024
Fermeate is a stealth-mode biotechnology company that specializes in photomolecular fermentation technology. This innovative approach aims to enhance sustainability and efficiency within the biomanufacturing industry.

CellCo

Seed Round in 2024
CellCo provides next generation biologics and biotherapies by integrating synthetic biology and AI.

Oobli

Series C in 2024
Oobli specializes in the development of healthy, protein-based sweeteners sourced from exotic plants. These unique compounds offer a flavorful experience without the calories typically associated with sugar, making them a suitable alternative for health-conscious consumers. The protein sweeteners are produced through fermentation, ensuring they have no glycemic impact and do not disrupt the gut microbiome. Oobli has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for several of its proteins, reinforcing their commitment to safety and quality. By providing a delicious and low-calorie option, Oobli aims to transform the way individuals approach sweeteners, allowing for healthier choices in everyday consumption.

Afynia Laboratories

Seed Round in 2024
Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Valanx Biotech

Seed Round in 2024
Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

Kegg

Series A in 2024
Kegg is a fertility tracking device that combines the functions of monitoring vaginal fluid and facilitating pelvic floor exercises. Founded in 2017 and based in San Francisco, California, Kegg utilizes advanced sensing technology to detect changes in cervical fluid, thereby enabling women to identify their fertile window and ovulation up to seven days in advance. This innovative approach provides essential data that enhances the diagnosis, monitoring, and treatment of women's reproductive health, significantly increasing the chances of natural conception. By offering an intuitive and effective solution, Kegg empowers women with the information they need to make informed decisions regarding their fertility.

CellCrine

Seed Round in 2024
CellCrine focuses on discovering enzymes that transform cell culture for the cell-based meats industry. CellCrine was founded in 2021and was headquartered in United, States.

MycoWorks

Series D in 2024
MycoWorks is a biotechnology company focused on developing sustainable, non-plastic and non-animal materials. Utilizing fungal mycelium, the company creates biodegradable alternatives to plastic foams, synthetic textiles, engineered woods, and leather. Their innovative products are designed for various applications, including aerospace, automobiles, apparel, and architectural interiors. By leveraging agricultural byproducts in a carbon-negative process, MycoWorks enables clients to access new types of leather that are grown rapidly and sustainably. This approach not only addresses environmental concerns but also offers practical solutions for industries seeking eco-friendly materials.

ViAn Therapeutics

Seed Round in 2024
VIAN Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop intended to replace traditional injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical trials, VIAN aims to meet significant unmet medical needs in the retinal disease market, which is valued at $15 billion. Additionally, the company is engaged in the creation of peptide drugs that enhance efficacy and safety for treating both ophthalmic and oncology-related conditions by targeting angiogenesis, thereby offering patients improved health outcomes.

OncoPrecision

Convertible Note in 2024
OncoPrecision is a company that focuses on improving cancer therapy outcomes by utilizing a patient micro avatar platform. This innovative platform employs single-cell high-throughput biology and machine learning to generate comprehensive patient-derived phenotypic biomarkers. By doing so, it enables oncologists to make informed, data-driven decisions regarding the selection of cancer therapies tailored to individual patients. The approach aims to increase the success rates of cancer treatments by ensuring that the right therapy is matched to the right patient, thus enhancing overall patient care and treatment effectiveness.

Prolific Machines

Series B in 2024
Prolific Machines is a biotechnology company based in San Francisco, California, founded in 2020. It specializes in developing advanced cell technologies aimed at transforming the production of cells for sustainable applications, particularly in the cultivated meat industry. The company focuses on high-scale precision cell-differentiation techniques that enhance the efficiency, quality, reproducibility, and sustainability of cell production. Additionally, Prolific Machines is engaged in research and development efforts related to clean meat and cell therapies, utilizing innovative approaches to create better sustainable options. Through its work, the company aims to promote a healthier future for both humanity and the planet.

VisusNano

Seed Round in 2024
VisusNano Ltd. is a pre-clinical company based in London, United Kingdom, focused on developing a drug-eluting intraocular lens implant for cataract surgery. Founded in 2016, the company aims to enhance patient outcomes by reducing the risks associated with cataract procedures, such as intraocular inflammation, infection, and opacification. This innovative lens technology eliminates the need for postoperative eye drops and laser treatments, positioning it as a potential game-changer in both human and veterinary cataract surgery markets. Through its advancements, VisusNano seeks to revolutionize the standard of care in ophthalmic procedures.

Bugbiome

Seed Round in 2024
BugBiome is a biotechnology company that develops eco-friendly bio-repellents to create natural pest control products. It focuses on identifying and enhancing beneficial microbes that deter pests organically, providing an alternative to traditional chemical methods. The company aims to minimize environmental impact and promote sustainable pest management practices, potentially benefiting sectors such as agriculture and households.

Avalo

Series A in 2024
Avalo is a plant biology company that employs interpretable machine learning, genomic discovery, and evolutionary theory to innovate crop development for future agricultural needs. Utilizing AI-assisted plant breeding, Avalo ensures that all its products are non-GMO and promote natural biodiversity. The company's core technology is a discovery engine that efficiently identifies the genetic foundations of complex traits, significantly shortening the time and reducing the costs associated with developing new crops. By focusing on traits such as drought tolerance, water-use efficiency, and nutrient density, Avalo's platform enhances crop evolution to adapt to changing climate conditions. This approach allows researchers to improve crop quality while providing diagnostic forecasting and gene discovery capabilities, ultimately advancing agricultural practices.

Sundew

Series B in 2024
Sundew is a biotechnology company founded in 2018 and headquartered in Copenhagen. The company specializes in providing biological services designed to treat aquatic pests and diseases through innovative solutions. Utilizing precision fermentation, Sundew develops environmentally-friendly products aimed at addressing challenges in the aquaculture market, including the management of invasive species and ecological issues such as red tides. By focusing on unmet needs within this sector, Sundew enables its clients to create effective, cost-efficient solutions that are both climate-friendly and sustainable.

HelEx

Convertible Note in 2024
Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Calder Biosciences

Seed Round in 2024
Calder Biosciences is focused on developing next-generation vaccines to address significant public health challenges posed by evolving viruses. Their innovative 3D-Vaxlock technology enhances vaccine stability and efficacy by creating molecular structures that maintain the most effective shapes of immunogens. This approach aims to improve protection against respiratory syncytial virus (RSV), particularly for the elderly, and to create a universal flu vaccine effective against all seasonal strains. By addressing the limitations of traditional vaccine designs, Calder aims to deliver solutions that provide better safety, durability, and effectiveness for at-risk populations. Ultimately, their goal is to prevent severe illnesses and reduce the healthcare burden, contributing to healthier lives for billions of people.

CroBio

Seed Round in 2024
CroBio Ltd is an agricultural biotechnology company based in Macclesfield, United Kingdom, founded in 2019 by experts in microbiology and engineering. The company focuses on developing environmentally sustainable solutions to combat global agricultural drought. Its technology leverages genetically engineered root-associated bacteria that produce a sponge-like biomaterial, facilitating biologically active water retention in soil. This innovative approach aims to improve soil health and enhance water management in agricultural practices.

Cell BioEngines

Pre Seed Round in 2024
Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies for the treatment of various human diseases, with a particular focus on oncology. The company has created a blood stem cell-derived epigenetic platform designed to address challenges related to donor source availability, cellular potency, and the complexities of manufacturing clinical-grade cell products. By leveraging this innovative platform, Cell BioEngines aims to produce cell-based therapies that can provide long-lasting benefits to patients, ultimately striving to transform cancer into a curable disease.

ClimateCrop

Seed Round in 2024
ClimateCrop is an agriculture technology company founded in 2021 and based in Ness Ziona. The company specializes in gene editing to enhance the ability of plants to store carbon and energy, thereby increasing crop yields in biomass and fruit production. By improving the resilience of crops to extreme weather conditions, ClimateCrop enables agricultural companies to better adapt to current and future climate challenges, ultimately leading to more sustainable and productive farming practices.

Finless Foods

Convertible Note in 2024
Finless Foods Inc. is a biotechnology company based in Emeryville, California, that specializes in producing seafood products for human consumption using cellular-agriculture technologies. Founded in 2017, the company focuses on growing marine-animal cells to create alternatives to traditional fish and seafood, including bluefin tuna. By offering a variety of responsibly produced food options, Finless Foods aims to cater to diverse tastes and dietary needs while promoting sustainability and better ocean health. The company's innovative approach provides consumers with healthy and accessible seafood alternatives, enabling them to maintain a balanced diet without compromising on flavor or variety.

Bloomlabs

Convertible Note in 2024
Bloomlabs provides a method to catalyze waste value by regenerating it as adaptable and appealing bio-plastics and textile fibers. It envisions a future in which outmoded, resource-intensive processes are phased out in favor of cutting-edge, sustainable, and scalable alternatives.

Cayuga Biotech

Convertible Note in 2024
Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

California Cultured

Series A in 2024
California Cultured is a food company based in Davis, California, that specializes in producing sustainable, lab-grown cocoa through advanced cellular agriculture techniques. Founded in 2020, the company aims to create cocoa that is less bitter and requires less sugar, enhancing the taste while promoting health benefits. By stimulating cocoa cells with common food ingredients, California Cultured ensures the growth of premium-quality cocoa without the ethical and environmental issues associated with traditional cocoa production, such as slavery and deforestation. This innovative approach allows customers to enjoy delicious cocoa products that are both sustainable and socially responsible.

Level Zero

Seed Round in 2024
Level Zero Health is a technology company specializing in advanced biosensor solutions. It develops wearable devices equipped with DNA-based sensors, designed to precisely monitor key endocrine biomarkers in real-time. By combining biochemistry and nanotechnology, the company collects novel data, empowering users to gain insights into their hormonal health.

Cauldron Ferm

Series A in 2024
Cauldron Ferm is a bio-acceleration process that exponentially scales up any precision fermented prototype to commercial quantities faster and with a lower cost of goods than any traditional production method.

DropGenie

Convertible Note in 2024
DropGenie is a biotechnology company founded in 2018 and based in Montreal, Canada. The company focuses on developing connected hardware that automates gene editing processes, thereby enhancing the efficiency of genetic engineering. Its platform streamlines liquid handling and experimental conditions, which helps scientists reduce costs while improving the standardization and reproducibility of their work. By generating standardized and compatible scientific information, DropGenie aims to accelerate the pace of discovery in the field of genetics, making advancements in gene editing more accessible to researchers.

Avisa Myko

Convertible Note in 2024
Avisa Myko Inc. is a biotechnology company based in San Francisco, California, specializing in the production of natural, water-soluble melanin. The company has developed a patented technology that allows for the large-scale and cost-effective manufacturing of melanin, which is used across various industries, including cosmetics, biomedicine, and environmental applications. Avisa Myko's melanin offers protection against ionizing radiation and is integrated into products such as latex, fabrics, laminated plastics, and glass. Additionally, the company is working on formulating a sunscreen that utilizes melanin as a natural ultraviolet blocker, eliminating the need for traditional chemical or mineral UV filters. By focusing on sustainable solutions, Avisa Myko aims to enhance human health and environmental safety through its innovative melanin products.

Reactosome

Seed Round in 2024
Reactosome is a biotechnology company that develops synthetic nuclei for gene therapy. Its core product, a synthetic nucleus, operates continuously within cells, mimicking the natural nucleus to affect multiple genes simultaneously. This approach aims to enhance the safety and longevity of gene expression, thereby enabling the healthcare industry to treat complex diseases such as cancers and age-related disorders more effectively.

Zymochem

Series A in 2024
ZymoChem, Inc. is a biotechnology company based in Emeryville, California, founded in 2013. It specializes in the development of eco-friendly chemicals and bioprocesses using engineered microbes to convert renewable feedstocks, such as sugars, into industrial chemicals. The company’s bio-manufacturing platform aims to produce bio-based materials while minimizing carbon emissions during production, thereby supporting a carbon-efficient economy. By establishing cost-effective bioprocesses and novel biosynthetic pathways, ZymoChem enables clients to reduce production costs and enhance their competitiveness in the market. Through its innovative approach, the company contributes to sustainable manufacturing practices and the advancement of a real-zero economy.

Feel Therapeutics

Venture Round in 2024
Feel Therapeutics is a digital precision medicine company focused on improving mental health through objective data and passive monitoring. It develops physiological and digital biomarkers alongside therapeutics that aid in the diagnosis, management, and care of mental health conditions. The company's platform includes proprietary medical-grade wearables, such as a wristband equipped with five embedded sensors, which collect biometric data. This data is analyzed using advanced computational methods to create digital biomarkers. By integrating these technologies, Feel Therapeutics aims to provide users with evidence-based insights that enhance their mental well-being and foster the development of lasting positive emotional habits.

Perfect Day

Series E in 2024
Perfect Day, Inc. is a pioneering company based in Emeryville, California, that specializes in producing animal-free dairy products. Founded in 2014, the company creates milk, cheese, yogurt, milk proteins, and ice cream that are nutritionally identical to traditional dairy but are made through a fermentation process using plant-based sugars. This innovative approach allows Perfect Day to deliver products that retain the taste, texture, and nutrition of conventional dairy while eliminating concerns related to food safety, environmental impact, and animal welfare. The company's commitment to sustainability and compassion results in nutrient-dense alternatives that are vegan, free from antibiotics, cholesterol, and lactose, catering to a growing market for healthier and more ethical food options.

Chronus Health

Convertible Note in 2024
Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Aequor

Seed Round in 2024
Aequor specializes in developing and marketing proprietary chemicals, cleaners, and water treatments aimed at removing and preventing biofilm, which contributes to various issues such as corrosion and contamination. Founded by a Marine and Medical Microbiologist, Aequor's innovative products are derived from newly discovered marine microbes that produce small molecules effective in biofilm removal and prevention. The company has achieved regulatory approval from the Environmental Protection Agency for several of its non-toxic products, which are classified as green and FDA-approved for food contact. Aequor provides a range of services, including testing, training, consulting, and custom product development, while collaborating with companies to offer comprehensive solutions. Its flagship product demonstrated significant efficacy in NASA's water reuse system on the International Space Station and has shown promise in various closed-loop systems. Aequor is also engaged in projects with the Department of Energy and the Department of Defense, focusing on environmental remediation and enhancing biomass production. As a Woman-Owned Small Business, Aequor is positioned to benefit from government set-asides and matching funds to further its market reach.

Lura Health

Seed Round in 2023
Lura Health has developed a groundbreaking non-invasive health monitoring platform that utilizes saliva as a diagnostic fluid, aiming to enhance clinical outcomes in chronic disease management. Founded in 2017 and based in Cambridge, Massachusetts, the company targets various chronic disease markets, including heart disease, chronic kidney disease, diabetes, and tooth decay. Its innovative sensors are integrated into patient-friendly orthodontic devices such as removable retainers and fixed braces. These sensors continuously measure analytes in saliva and automatically transmit data to a smartphone application, allowing users to track key diagnostic metrics related to their oral health. By enabling individuals to monitor their health in real-time, Lura Health seeks to improve personal health management and empower users to take charge of their well-being.

Unlocked Labs

Seed Round in 2023
Unlocked Labs specializes in developing innovative probiotics aimed at addressing chronic health conditions by utilizing genetically optimized microbial strains. The company focuses on activating dormant microbial abilities to effectively digest compounds that can lead to health issues. Their first product targets the risk of kidney stones by breaking down stone-forming compounds derived from healthy foods like leafy vegetables. Unlocked Labs employs alternative regulatory pathways to expedite the availability of safe and effective probiotic solutions for consumers. By harnessing the natural detoxifying capabilities of symbiotic microbes, their products aim to reduce acid levels in the body, making them both affordable and accessible to a wide audience.

RyboDyn

Seed Round in 2023
RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to detect and eliminate cancer from within the body. The company is dedicated to advancing scientific breakthroughs that lead to new classes of treatments, providing significant improvements in medicine. RyboDyn's work is particularly concentrated on creating upgraded therapies for serious diseases, including terminal conditions, with the goal of enhancing patient outcomes and expanding treatment options.

Atlantic Fish Company

Pre Seed Round in 2023
Atlantic Fish Company is focused on producing cultivated seafood through cellular agriculture, operating from its headquarters in Raleigh-Durham, North Carolina. The company aims to provide sustainable seafood options by cultivating fish in a controlled environment. This innovative approach allows Atlantic Fish Company to offer fresh fish meat that maintains the natural taste while minimizing the environmental impact associated with traditional fishing practices. By leveraging cellular agriculture, the company seeks to meet the growing demand for sustainable protein sources.

Prellis Biologics

Series C in 2023
Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Tômtex

Seed Round in 2023
Tômtex specializes in recycling agricultural waste to develop sustainable and bio-based materials that serve as alternatives to traditional faux and animal leather. By utilizing resources such as shellfish waste, mushrooms, and coffee grounds, the company creates practical materials that minimize environmental impact and promote biodegradability. Tômtex's innovative approach not only provides economical solutions for businesses but also helps customers reduce their greenhouse gas emissions and overall carbon footprint, contributing to a more sustainable future.

Hypercell Technologies

Seed Round in 2023
Hypercell Technologies focuses on developing innovative diagnostic tools and monoclonal antibodies aimed at controlling infectious diseases in animals. The company employs molecular biology techniques to create accurate in-farm diagnostic tools that deliver results in under one hour. This rapid testing capability, combined with their antibodies, allows veterinarians to effectively manage and mitigate the spread of viruses within production animal populations. Hypercell Technologies is committed to preventing potential pandemics in humans by addressing the root causes of infectious diseases in animal reservoirs.

Valanx Biotech

Seed Round in 2023
Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

Lillianah Technologies

Seed Round in 2023
Lillianah is a team of scientists dedicated to addressing environmental challenges through innovative carbon capture technology. Their focus is on optimizing the biological pump in oceans to restore balance to marine ecosystems adversely affected by pollution, fertilizer runoff, and various external factors. By harnessing the potential of oceans, Lillianah aims to reverse the negative impacts on the environment, contributing to a healthier planet.

Gozen

Seed Round in 2023
Gozen is a material science platform focused on developing biomaterials for a sustainable future. By utilizing microorganisms and agricultural and industrial organic wastes, the company creates innovative biomaterials through a biomimicry approach, merging science with artistic expression. Gozen specializes in producing fully biodegradable, biocompatible, and non-toxic alternatives to traditional leather, providing the fashion industry with sustainable options that promote a natural connection to the environment and emphasize the importance of ecological balance.

Biofluff

Seed Round in 2023
BioFluff specializes in the production of plant-based fur aimed at replacing traditional animal and plastic furs in the fashion industry. Utilizing a patented process along with retrofitted equipment for faux-fur manufacturing, the company is establishing a scalable production model for its sustainable materials. BioFluff's products are made from organic renewable fiber plants and are developed without gene splicing, gene editing, or the use of petrochemicals and unsustainable raw-oil derivatives. Additionally, the company offers customization services, allowing customers to personalize various aspects of their products, including fur length, fiber density, color, and insulation properties. This commitment to sustainability positions BioFluff as a leader in providing luxury materials that align with eco-friendly practices.

Pyrone Systems

Seed Round in 2023
Pyrone Systems is a company focused on developing biopesticides that integrate biological and chemical principles to create safe and effective products. Founded in 2021, the company employs scalable methodologies to produce bio-based solutions that aim to replace harmful petrochemicals. By prioritizing sustainability, Pyrone Systems seeks to offer environmentally friendly alternatives in the agrochemical industry, thereby contributing to a reduction in the use of hazardous substances.

BioAesthetics

Convertible Note in 2023
BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

FREZENT

Seed Round in 2023
FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

Gatehouse Bio

Convertible Note in 2023
Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Biomr

Seed Round in 2023
Biomr is a fibre technology company that develops and produces eco-friendly, waterproof, and oil-resistant coatings for the fashion industry. Utilizing renewable organic sources and free from chemicals, their innovative coatings are designed to protect clothing from various substances, enabling clients to create durable, sustainable garments.

Diptera.ai

Convertible Note in 2023
Diptera.ai, based in Jerusalem, Israel, specializes in innovative mosquito control solutions. The company focuses on a biological method that utilizes sterile insect techniques, specifically by releasing sterile male mosquitoes through a ready-to-use module over a period of weeks. This technology incorporates advanced optics, computer vision, and artificial intelligence, making it both affordable and accessible for municipal corporations. By eliminating the need for mosquito rearing and sorting facilities, Diptera.ai enables large-scale mosquito control efforts, addressing public health concerns efficiently.

Calder Biosciences

Seed Round in 2023
Calder Biosciences is focused on developing next-generation vaccines to address significant public health challenges posed by evolving viruses. Their innovative 3D-Vaxlock technology enhances vaccine stability and efficacy by creating molecular structures that maintain the most effective shapes of immunogens. This approach aims to improve protection against respiratory syncytial virus (RSV), particularly for the elderly, and to create a universal flu vaccine effective against all seasonal strains. By addressing the limitations of traditional vaccine designs, Calder aims to deliver solutions that provide better safety, durability, and effectiveness for at-risk populations. Ultimately, their goal is to prevent severe illnesses and reduce the healthcare burden, contributing to healthier lives for billions of people.

BryoSphere

Seed Round in 2023
BryoSphere is a company specializing in the manufacturing of specialty chemicals, employing moss plants and biotechnology methods in the production of their goods. The company is currently focused on the development of two key products: one for addressing skin hyperpigmentation in topical treatments, and another as an anti-cancer drug.

Xias Bio

Seed Round in 2023
Xias Bio is a biotechnology startup focused on producing recombinant proteins that enhance the delivery of functional ingredients for various sectors, including research, beauty, and healthcare. The company specializes in developing non-immunogenic natural motifs, which provide a superior platform for creating soluble and active ingredients with desirable properties such as improved gel and film formation and antioxidant effects. By offering an adaptable, animal product-free biomaterial, Xias Bio delivers tailored biological functionalities that outperform traditional synthetic and animal-based products. This innovation enables pharmaceutical and cosmetic companies to access non-toxic, non-immunogenic alternatives for a wide range of applications.

Veloz Bio

Seed Round in 2023
Veloz Bio is a biotechnology company established in 2021 and located in Monterrey, Nuevo León. The company specializes in molecular farming to develop and manufacture sustainable and affordable animal-free and alternative proteins. By leveraging efficient plant metabolism, Veloz Bio has created a rapid protein production system that enables scalable growth of new proteins. This innovation allows biotech firms to gain expertise in essential areas of protein production, including supercritical fluid extraction and membrane purification. Through its focus on alternative proteins, Veloz Bio aims to contribute to a more sustainable food supply.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.